Skip to content

Research at St Andrews

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Research output: Contribution to journalArticle

Abstract

Background Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events.

Methods The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627).
Findings Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92).
Interpretation These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention.
Close

Details

Original languageEnglish
Pages (from-to)2613-2623
Number of pages11
JournalLancet
Volume393
Issue number10191
Early online date22 May 2019
DOIs
Publication statusPublished - 29 Jun 2019

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Do statins have an effect on depressive symptoms? A systematic review and meta-analysis

    Yatham, M. S., Yatham, K. S., Ravindran, A. V. & Sullivan, F., 1 Oct 2019, In : Journal of Affective Disorders. 257, p. 55-63 9 p.

    Research output: Contribution to journalArticle

  2. Unconditional and conditional monetary incentives to increase response to mailed questionnaires: a randomized controlled study within a trial (SWAT)

    Young, B., Bedford, L., das Nair, R., Gallant, S., Littleford, R., Robertson, J. F. R., Schembri, S., Sullivan, F. M., Vedhara, K., Kendrick, D. & ECLS study team, 22 Jul 2019, In : Journal of Evaluation in Clinical Practice. Early View

    Research output: Contribution to journalArticle

  3. The impact of treatment adherence for patients with diabetes and hypertension on cardiovascular disease risk: a protocol for a retrospective cohort study, 2008-2018

    Su, M., Haldane, V., Upshur, R., Sullivan, F., Garda, F. L. A., Greiver, M. & Wei, X., 31 May 2019, In : JMIR Research Protocols. 8, 5, 11 p., e13571.

    Research output: Contribution to journalArticle

  4. Factors associated with recruitment to randomised controlled trials in general practice: protocol for a systematic review

    Moffat, K. R., Cannon, P., Shi, W. & Sullivan, F., 10 May 2019, In : Trials. 20, 4 p., 66.

    Research output: Contribution to journalArticle

  5. Podiatry interventions to prevent falls in older people: a systematic review and meta-analysis

    Wylie, G., Torrens, C., Campbell, P., Frost, H., Gordon, A. L., Menz, H. B., Skelton, D. A., Sullivan, F., Witham, M. D. & Morris, J., May 2019, In : Age and Ageing. 48, 3, p. 327–336 10 p.

    Research output: Contribution to journalArticle

Related by journal

  1. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial

    FOCUS Trial Collaboration & Sullivan, F., 19 Jan 2019, In : Lancet. 393, 10168, p. 265-274 10 p.

    Research output: Contribution to journalArticle

  2. Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial

    Thwaites, G. E., Scarborough, M., Szubert, A., Nsutebu, E., Tilley, R., Greig, J., Wyllie, S. A., Wilson, P., Auckland, C., Cairns, J., Ward, D., Lal, P., Guleri, A., Jenkins, N., Sutton, J., Wiselka, M., Armando, G-R., Graham, C., Chadwick, P. R., Barlow, G. & 18 others, Gordon, N. C., Young, B., Meisner, S., McWhinney, P., Price, D. A., Harvey, D., Nayar, D., Jeyaratnam, D., Planche, T., Minton, J., Hudson, F., Hopkins, S., Williams, J., Török, M. E., Llewelyn, M. J., Edgeworth, J. D., Walker, A. S. & United Kingdom Clinical Infection Research Group (UKCIRG), 17 Feb 2018, In : Lancet. 391, 10121, p. 668-678 11 p.

    Research output: Contribution to journalArticle

  3. Management of multimorbidity using a patient-centred care model: a pragmatic cluster-randomised trial of the 3D approach

    Salisbury, C., Man, M-S., Bower, P., Guthrie, B., Chaplin, K., Gaunt, D. M., Brookes, S., Fitzpatrick, B., Gardner, C., Hollinghurst, S., Lee, V., McLeod, J., Mann, C., Moffat, K. R. & Mercer, S. W., 7 Jul 2018, In : Lancet. 392, 10141, p. 41-50

    Research output: Contribution to journalArticle

  4. Effectiveness of early lens extraction for the treatment of primary angle-closure glaucoma (EAGLE): a randomised controlled trial

    Azuara-Blanco, A., Burr, J., Ramsay, C., Cooper, D., Foster, P. J., Friedman, D. S., Scotland, G., Javanbakht, M., Cochrane, C., Norrie, J. & EAGLE study group, 1 Oct 2016, In : Lancet. 388, 10052, p. 1389-1397 9 p.

    Research output: Contribution to journalArticle

ID: 259078608

Top